BBIO News and Press, BridgeBio Pharma Inc. From 02/24/26

2026-02-24 16:06:33 ET More on BridgeBio Pharma BridgeBio Pharma, Inc. (BBIO) Discusses Positive Phase 3 PROPEL 3 Results for Infigratinib in Children With Achondroplasia Transcript BridgeBio Pharma, Inc. (BBIO) Discusses Positive Phase 3 PROPEL 3 Results for Infigratinib in...

PALO ALTO, Calif., Feb. 17, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a biopharmaceutical company focused on developing medicines for genetic conditions, today announced that it will release its fourth quarter and fu...

2026-02-12 21:15:00 ET The following segment was excerpted from the Allspring Growth Fund Q4 2025 Commentary. ... Read the full article on Seeking Alpha For further details see: Allspring Growth Fund Q4 2025 Fund Performers And Detractors

2026-02-12 17:54:19 ET BridgeBio Pharma, Inc. (BBIO) Discusses Positive Phase 3 PROPEL 3 Results for Infigratinib in Children With Achondroplasia February 12, 2026 8:00 AM EST... Read the full article on Seeking Alpha For further details see: BridgeBio Pharma, Inc. (BBIO) Di...

2026-02-12 15:04:10 ET Andrew Tsai from Jefferies issued a price target of $100.00 for BBIO on 2026-02-12 19:07:50. The adjusted price target was set to $100.00. At the time of the announcement, BBIO was trading at $76.06. The overall price target consensus is at $96.82 ...

2026-02-12 14:15:07 ET Jefferies analyst issues BUY recommendation for BBIO on February 12, 2026 07:07PM ET. The previous analyst recommendation was Buy. BBIO was trading at $77.67 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current a...

2026-02-12 09:20:23 ET Denver, Colorado- Markets are digesting a wave of corporate developments spanning biotech innovation, AI infrastructure, edge computing and digital asset tokenization, with several companies delivering headline-grabbing updates that could shape sector narratives in 20...

2026-02-12 08:19:29 ET More on BridgeBio Pharma BridgeBio: Initiating At A Neutral Rating, Stock Priced At Perfection BridgeBio Pharma, Inc. (BBIO) Presents at 44th Annual J.P. Morgan Healthcare Conference Prepared Remarks Transcript BridgeBio Pharma, Inc. (BBIO) Pre...

- PROPEL 3 successfully met the primary endpoint of change from baseline in AHV at Week 52 (p<0.0001) - Change from baseline in AHV was superior to placebo at Week 52 with a mean treatment difference against placebo of +2.10 cm/year; the LS mean was +1.74 cm/year - In a pre-specified explo...

2026-02-09 01:10:13 ET Initiating BridgeBio with a neutral rating I initiate coverage of Bridge Bio ( BBIO ) with a neutral rating, which reflects the balance between tangible de-risking following the US approval/early commercialization of acoramidis (Attruby) in the transthyret...